Brian K Halak insider trades: Obalon Therapeutics (OBLN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Brian reports to the SEC
and 19 more companies
Open-market buys and sales
106 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 6, 2019 | OBLN | ↑ Buy | 250,000 | $4.00 | $1.0M | Direct | Aug 8, 2019 (2d) |
| Nov 6, 2018 | DRNA | ↓ Sell | 332,521 | $13.33 | $4.4M | By Domain Partners VIII, L.P. | Nov 6, 2018 (0d) |
| Nov 6, 2018 | DRNA | ↓ Sell | 2,479 | $13.33 | $33K | By DP VIII Associates, L.P. | Nov 6, 2018 (0d) |
| Nov 1, 2018 | DRNA | ↓ Sell | 560,119 | $13.66 | $7.7M | By Domain Partners VIII, L.P. | Nov 1, 2018 (0d) |
| Nov 1, 2018 | DRNA | ↓ Sell | 4,181 | $13.66 | $57K | By DP VIII Associates, L.P. | Nov 1, 2018 (0d) |
| Aug 23, 2018 | OBLN | ↑ Buy | 1,648,359 | $1.82 | $3.0M | Direct | Aug 27, 2018 (4d) |
| Aug 23, 2018 | BNGO | ↑ Buy | 15,000 | $6.13 | $92K | Direct | Aug 27, 2018 (4d) |
| May 26, 2016 | EVOK | ↓ Sell | 344,120 | $4.70 | $1.6M | Direct | May 27, 2016 (1d) |
| May 26, 2016 | EVOK | ↓ Sell | 5,880 | $4.70 | $28K | Direct | May 27, 2016 (1d) |
| Apr 27, 2016 | EVOK | ↓ Sell | 5,095 | $5.07 | $26K | Direct | Apr 27, 2016 (0d) |
| Apr 27, 2016 | EVOK | ↓ Sell | 82 | $5.07 | $415 | Direct | Apr 27, 2016 (0d) |
| Apr 20, 2016 | EVOK | ↓ Sell | 41,478 | $5.35 | $222K | Direct | Apr 21, 2016 (1d) |
| Apr 20, 2016 | EVOK | ↓ Sell | 708 | $5.35 | $4K | Direct | Apr 21, 2016 (1d) |
| Apr 11, 2016 | EVOK | ↓ Sell | 4,348 | $5.22 | $23K | Direct | Apr 13, 2016 (2d) |
| Apr 11, 2016 | EVOK | ↓ Sell | 75 | $5.22 | $392 | Direct | Apr 13, 2016 (2d) |
| Apr 8, 2016 | EVOK | ↓ Sell | 51,004 | $5.28 | $269K | Direct | Apr 8, 2016 (0d) |
| Apr 8, 2016 | EVOK | ↓ Sell | 874 | $5.28 | $5K | Direct | Apr 8, 2016 (0d) |
| Aug 18, 2015 | EVOK | ↓ Sell | 11,836 | $7.02 | $83K | Direct | Aug 20, 2015 (2d) |
| Aug 18, 2015 | EVOK | ↓ Sell | 202 | $7.02 | $1K | Direct | Aug 20, 2015 (2d) |
| May 4, 2015 | TBRA | ↑ Buy | 277,777 | $10.62 | $2.9M | Direct | May 6, 2015 (2d) |
| Apr 16, 2015 | EVOK | ↓ Sell | 50,163 | $7.29 | $366K | Direct | Apr 16, 2015 (0d) |
| Apr 16, 2015 | EVOK | ↓ Sell | 857 | $7.29 | $6K | Direct | Apr 16, 2015 (0d) |
| Nov 25, 2014 | NEOT | ↑ Buy | 70,000 | $14.00 | $980K | Direct | Nov 26, 2014 (1d) |
| Oct 21, 2014 | ESPR | ↑ Buy | 500,000 | $20.00 | $10.0M | Direct | Oct 21, 2014 (0d) |
| Oct 21, 2014 | ATRA | ↑ Buy | 248,159 | $11.00 | $2.7M | Direct | Oct 21, 2014 (0d) |
| Oct 21, 2014 | ATRA | ↑ Buy | 1,841 | $11.00 | $20K | Direct | Oct 21, 2014 (0d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 988,285 | $6.03 | $6.0M | By Domain Partners VIII, L.P. | Jul 16, 2013 (1d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 331,873 | $6.03 | $2.0M | By Domain Partners VI, L.P. | Jul 16, 2013 (1d) |
| Jul 15, 2013 | OCRX | ↑ Buy | 7,333 | $6.03 | $44K | By DP VIII Associates, L.P. | Jul 16, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 280,923 | $14.00 | $3.9M | By Domain Partners VII, L.P. | Jul 2, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 4,791 | $14.00 | $67K | By DP VII Associates, L.P. | Jul 2, 2013 (1d) |
| Jun 4, 2013 | CLVS | ↓ Sell | 159,192 | $64.58 | $10.3M | Direct | Jun 5, 2013 (1d) |
| Jun 4, 2013 | CLVS | ↓ Sell | 2,779 | $64.58 | $179K | Direct | Jun 5, 2013 (1d) |
| Apr 15, 2013 | CADX | ↓ Sell | 23,210 | $6.62 | $154K | Direct | Apr 17, 2013 (2d) |
| Apr 10, 2013 | CADX | ↓ Sell | 25,170 | $6.62 | $167K | Direct | Apr 10, 2013 (0d) |
| Mar 21, 2013 | CADX | ↓ Sell | 4,374 | $5.35 | $23K | Direct | Mar 22, 2013 (1d) |
| Mar 21, 2013 | CADX | ↓ Sell | 893 | $5.49 | $5K | Direct | Mar 22, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 13,435 | $5.20 | $70K | Direct | Mar 21, 2013 (1d) |
| Mar 20, 2013 | CADX | ↓ Sell | 226 | $5.20 | $1K | Direct | Mar 21, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 17,656 | $5.23 | $92K | Direct | Mar 19, 2013 (1d) |
| Mar 18, 2013 | CADX | ↓ Sell | 298 | $5.23 | $2K | Direct | Mar 19, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 12,753 | $5.38 | $69K | Direct | Mar 15, 2013 (1d) |
| Mar 14, 2013 | CADX | ↓ Sell | 216 | $5.38 | $1K | Direct | Mar 15, 2013 (1d) |
| Mar 12, 2013 | CADX | ↓ Sell | 10,464 | $5.36 | $56K | Direct | Mar 13, 2013 (1d) |
| Mar 12, 2013 | CADX | ↓ Sell | 177 | $5.36 | $949 | Direct | Mar 13, 2013 (1d) |
| Mar 8, 2013 | CADX | ↓ Sell | 17,855 | $5.25 | $94K | Direct | Mar 11, 2013 (3d) |
| Mar 8, 2013 | CADX | ↓ Sell | 303 | $5.25 | $2K | Direct | Mar 11, 2013 (3d) |
| Mar 6, 2013 | CADX | ↓ Sell | 7,878 | $5.03 | $40K | Direct | Mar 7, 2013 (1d) |
| Mar 6, 2013 | CADX | ↓ Sell | 134 | $5.03 | $675 | Direct | Mar 7, 2013 (1d) |
| Mar 6, 2013 | CLVS | ↓ Sell | 250,000 | $24.59 | $6.1M | Direct | Mar 6, 2013 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Brian K Halak's insider trades
Brian K Halak is a 10% owner of Obalon Therapeutics (OBLN). Since Mar 24, 2008, Brian has reported 47 open-market purchases worth $106.5M and 59 sales worth $33.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (28 filings), grants and awards (25 filings), other transactions (23 filings), shares returned to the company (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OBLN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.